Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C

The Kyushu University Liver Disease Study (KULDS) Group

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

Aim: Although there is much evidence of an antitumor effect of pegylated interferon (IFN)-α-based treatment, limited data is available about that of IFN-β-based treatment. Our goal was to evaluate the impact of IFN-β plus ribavirin (RBV) treatment on the suppression of hepatocellular carcinoma (HCC). Methods: This retrospective, multicenter study consisted of 124 chronic hepatitis C patients who were treated with IFN-β plus RBV treatment, including 61 with advanced fibrosis and five with pretreatment HCC. All participants were followed for a median of 2.8years (range, 2.2-3.2) after the end of their antiviral treatment. The data of 112 patients who finished the treatment were available for analysis. Cox proportional hazard analyses were performed to determine factors significantly associated with HCC development. Cumulative incidence curves for HCC were plotted using the Kaplan-Meier method and differences between groups were assessed using the log-rank test. Results: The 2.9% rate of HCC development of patients with sustained virological response (SVR) was significantly lower (P=0.027) than the 15.9% of non-SVR patients. Interestingly, no significant difference was observed between the rates of HCC development of patients with and without advanced fibrosis (P=0.733), even though the SVR rate of patients with advanced fibrosis was significantly lower than that of those without advanced fibrosis (P<0.001). Stepwise multivariable Cox analysis extracted that only SVR was significantly associated with HCC development (hazard ratio, 0.20; 95% confidence interval, 0.03-0.84, P=0.027). Conclusion: SVR was significantly associated with a lower risk of HCC development after IFN-β plus RBV treatment.

元の言語英語
ページ(範囲)E174-E180
ジャーナルHepatology Research
46
発行部数3
DOI
出版物ステータス出版済み - 3 1 2016

Fingerprint

Ribavirin
Interferon-beta
Chronic Hepatitis C
Hepatocellular Carcinoma
Interferons
Fibrosis
Therapeutics
Multicenter Studies
Antiviral Agents
Retrospective Studies
Confidence Intervals
Incidence

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

これを引用

Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C. / The Kyushu University Liver Disease Study (KULDS) Group.

:: Hepatology Research, 巻 46, 番号 3, 01.03.2016, p. E174-E180.

研究成果: ジャーナルへの寄稿記事

@article{37cc00faffb748cf9ca16c0c5a53a6ff,
title = "Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C",
abstract = "Aim: Although there is much evidence of an antitumor effect of pegylated interferon (IFN)-α-based treatment, limited data is available about that of IFN-β-based treatment. Our goal was to evaluate the impact of IFN-β plus ribavirin (RBV) treatment on the suppression of hepatocellular carcinoma (HCC). Methods: This retrospective, multicenter study consisted of 124 chronic hepatitis C patients who were treated with IFN-β plus RBV treatment, including 61 with advanced fibrosis and five with pretreatment HCC. All participants were followed for a median of 2.8years (range, 2.2-3.2) after the end of their antiviral treatment. The data of 112 patients who finished the treatment were available for analysis. Cox proportional hazard analyses were performed to determine factors significantly associated with HCC development. Cumulative incidence curves for HCC were plotted using the Kaplan-Meier method and differences between groups were assessed using the log-rank test. Results: The 2.9{\%} rate of HCC development of patients with sustained virological response (SVR) was significantly lower (P=0.027) than the 15.9{\%} of non-SVR patients. Interestingly, no significant difference was observed between the rates of HCC development of patients with and without advanced fibrosis (P=0.733), even though the SVR rate of patients with advanced fibrosis was significantly lower than that of those without advanced fibrosis (P<0.001). Stepwise multivariable Cox analysis extracted that only SVR was significantly associated with HCC development (hazard ratio, 0.20; 95{\%} confidence interval, 0.03-0.84, P=0.027). Conclusion: SVR was significantly associated with a lower risk of HCC development after IFN-β plus RBV treatment.",
author = "{The Kyushu University Liver Disease Study (KULDS) Group} and Hiroaki Ikezaki and Hideyuki Nomura and Norihiro Furusyo and Eiichi Ogawa and Eiji Kajiwara and Kazuhiro Takahashi and Akira Kawano and Toshihiro Maruyama and Yuichi Tanabe and Takeaki Satoh and Makoto Nakamuta and Kazuhiro Kotoh and Koichi Azuma and Kazufumi Dohmen and Shinji Shimoda and Jun Hayashi",
year = "2016",
month = "3",
day = "1",
doi = "10.1111/hepr.12555",
language = "English",
volume = "46",
pages = "E174--E180",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Efficacy of interferon-beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C

AU - The Kyushu University Liver Disease Study (KULDS) Group

AU - Ikezaki, Hiroaki

AU - Nomura, Hideyuki

AU - Furusyo, Norihiro

AU - Ogawa, Eiichi

AU - Kajiwara, Eiji

AU - Takahashi, Kazuhiro

AU - Kawano, Akira

AU - Maruyama, Toshihiro

AU - Tanabe, Yuichi

AU - Satoh, Takeaki

AU - Nakamuta, Makoto

AU - Kotoh, Kazuhiro

AU - Azuma, Koichi

AU - Dohmen, Kazufumi

AU - Shimoda, Shinji

AU - Hayashi, Jun

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aim: Although there is much evidence of an antitumor effect of pegylated interferon (IFN)-α-based treatment, limited data is available about that of IFN-β-based treatment. Our goal was to evaluate the impact of IFN-β plus ribavirin (RBV) treatment on the suppression of hepatocellular carcinoma (HCC). Methods: This retrospective, multicenter study consisted of 124 chronic hepatitis C patients who were treated with IFN-β plus RBV treatment, including 61 with advanced fibrosis and five with pretreatment HCC. All participants were followed for a median of 2.8years (range, 2.2-3.2) after the end of their antiviral treatment. The data of 112 patients who finished the treatment were available for analysis. Cox proportional hazard analyses were performed to determine factors significantly associated with HCC development. Cumulative incidence curves for HCC were plotted using the Kaplan-Meier method and differences between groups were assessed using the log-rank test. Results: The 2.9% rate of HCC development of patients with sustained virological response (SVR) was significantly lower (P=0.027) than the 15.9% of non-SVR patients. Interestingly, no significant difference was observed between the rates of HCC development of patients with and without advanced fibrosis (P=0.733), even though the SVR rate of patients with advanced fibrosis was significantly lower than that of those without advanced fibrosis (P<0.001). Stepwise multivariable Cox analysis extracted that only SVR was significantly associated with HCC development (hazard ratio, 0.20; 95% confidence interval, 0.03-0.84, P=0.027). Conclusion: SVR was significantly associated with a lower risk of HCC development after IFN-β plus RBV treatment.

AB - Aim: Although there is much evidence of an antitumor effect of pegylated interferon (IFN)-α-based treatment, limited data is available about that of IFN-β-based treatment. Our goal was to evaluate the impact of IFN-β plus ribavirin (RBV) treatment on the suppression of hepatocellular carcinoma (HCC). Methods: This retrospective, multicenter study consisted of 124 chronic hepatitis C patients who were treated with IFN-β plus RBV treatment, including 61 with advanced fibrosis and five with pretreatment HCC. All participants were followed for a median of 2.8years (range, 2.2-3.2) after the end of their antiviral treatment. The data of 112 patients who finished the treatment were available for analysis. Cox proportional hazard analyses were performed to determine factors significantly associated with HCC development. Cumulative incidence curves for HCC were plotted using the Kaplan-Meier method and differences between groups were assessed using the log-rank test. Results: The 2.9% rate of HCC development of patients with sustained virological response (SVR) was significantly lower (P=0.027) than the 15.9% of non-SVR patients. Interestingly, no significant difference was observed between the rates of HCC development of patients with and without advanced fibrosis (P=0.733), even though the SVR rate of patients with advanced fibrosis was significantly lower than that of those without advanced fibrosis (P<0.001). Stepwise multivariable Cox analysis extracted that only SVR was significantly associated with HCC development (hazard ratio, 0.20; 95% confidence interval, 0.03-0.84, P=0.027). Conclusion: SVR was significantly associated with a lower risk of HCC development after IFN-β plus RBV treatment.

UR - http://www.scopus.com/inward/record.url?scp=84940676581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940676581&partnerID=8YFLogxK

U2 - 10.1111/hepr.12555

DO - 10.1111/hepr.12555

M3 - Article

AN - SCOPUS:84940676581

VL - 46

SP - E174-E180

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 3

ER -